RT Journal Article
SR Electronic
T1 COVID-19; Systematic and literature review of transmission, case definitions, clinical management and clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20102475
DO 10.1101/2020.05.14.20102475
A1 McArthur, Laura
A1 Sakthivel, DhanaSekaran
A1 Ataide, Ricardo
A1 Chan, Felicia
A1 Richards, Jack S.
A1 Narh, Charles A.
YR 2020
UL http://medrxiv.org/content/early/2020/05/20/2020.05.14.20102475.abstract
AB Background SARS-CoV-2, the viral agent responsible for coronavirus disease 2019 (COVID-19) was identified in Wuhan, China at the end of December 2019. It rapidly spread to the rest of the world, and was declared a Public Health Emergency of International Concern on the 30th of January 2020. Our understanding of the virus, it’s clinical manifestations and treatment options continues to evolve at an unparalleled pace.Objective This review sought to summarise the key literature regarding transmission, case definitions, clinical management and trials, and performed a systematic review of reported clinical data on COVID-19.Synthesis methods Two reviewers selected all the literature independently, and extracted information according to pre-defined topics.Results COVID-19 is pandemic with ∼4 million cases and 270,000 deaths in 210 countries as of 8 May 2020. Our review of reports showed that SARS-CoV-2 was mainly transmitted via inhalation of respiratory droplets containing the virus and had an incubation period of four to six days. The commonly reported symptoms were fever (80%) and cough (60%) across the spectrum of clinical disease – mild, moderate, severe and critical. Categorization of these cases for home care or hospital management need to be well defined considering the age of the patient and the presence of underlying co-morbidities. The case definitions we reviewed varied among affected countries, which could have contributed to the differences observed in the mean case fatality rates among continents – Oceania (1%), Asia (3%), Africa (4%), South America (5%), North America (6%) and Europe (10%). Asymptomatic cases, which constituted an estimated 80% of COVID-19 cases are a huge threat to control efforts.Conclusion The presence of fever and cough may be sufficient to warrant a COVID-19 testing but using these symptoms in isolation will miss a proportion of cases. A clear definition of a COVID-19 case is important for managing, treating and tracking clinical illness. While several treatments are in development or in clinical trials for COVID-19, home care of mild/moderate cases and hospital care for severe and critical cases remain the recommended management for the disease. Quarantine measures and social distancing can help control the spread of SARS-CoV-2.Competing Interest StatementZiP Diagnostics is commercialising a COVID-19 point of care test. CAN, DS and JSR have part-time employment at ZiP.Funding StatementThis work was supported by the National Health and Medical Research Council (NHMRC) of Australia [APP1161076 to J.S.R.]. Burnet Institute received funding from the NHMRC Independent Research Institutes Infrastructure Support Scheme, and the Victorian State Government Operational Infrastructure Support Scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data have been included in the manuscript.